Fractyl Health, Inc. has announced the entry into a significant underwriting agreement with Ladenburg Thalmann & Co. Inc. This agreement pertains to the underwritten offering, issuance, and sale of 19,047,619 shares of the company's common stock, alongside accompanying Tranche A and Tranche B Warrants, all priced at a combined offering of $1.05 per share with accompanying warrants. The net proceeds from this offering will be utilized to bolster Fractyl Health's Revita and Rejuva pipeline programs and for general corporate purposes. Additionally, Fractyl Health has committed to holding a special stockholder meeting to seek approval for the Tranche B Warrants within 60 days of closing the offering, with strong backing from the company's board and key stakeholders.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。